Geoff  McDonough net worth and biography

Geoff McDonough Biography and Net Worth

Geoff formerly served as president and chief executive officer of Swedish Orphan Biovitrum AB (Sobi) from 2011– 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including president of Genzyme Europe and senior vice president and general manager of the global lysosomal storage disease business. Geoff has a Bachelor of Science in biology and a Bachelor of Arts in philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained his doctor of medicine at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children's Hospital.

What is Geoff McDonough's net worth?

The estimated net worth of Geoff McDonough is at least $4.82 million as of April 23rd, 2021. Dr. McDonough owns 1,184,080 shares of Generation Bio stock worth more than $4,819,206 as of March 28th. This net worth estimate does not reflect any other assets that Dr. McDonough may own. Additionally, Dr. McDonough receives an annual salary of $939,090.00 as CEO at Generation Bio. Learn More about Geoff McDonough's net worth.

How old is Geoff McDonough?

Dr. McDonough is currently 54 years old. There are 7 older executives and no younger executives at Generation Bio. Learn More on Geoff McDonough's age.

What is Geoff McDonough's salary?

As the CEO of Generation Bio Co., Dr. McDonough earns $939,090.00 per year. Learn More on Geoff McDonough's salary.

How do I contact Geoff McDonough?

The corporate mailing address for Dr. McDonough and other Generation Bio executives is 301 BINNEY STREET, CAMBRIDGE MA, 02142. Generation Bio can also be reached via phone at 617-655-7500 and via email at [email protected]. Learn More on Geoff McDonough's contact information.

Has Geoff McDonough been buying or selling shares of Generation Bio?

Geoff McDonough has not been actively trading shares of Generation Bio within the last three months. Most recently, Geoff Mcdonough sold 10,000 shares of the business's stock in a transaction on Friday, April 23rd. The shares were sold at an average price of $35.10, for a transaction totalling $351,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,184,080 shares of the company's stock, valued at $41,561,208. Learn More on Geoff McDonough's trading history.

Who are Generation Bio's active insiders?

Generation Bio's insider roster includes Douglas Kerr (Insider), Geoff McDonough (CEO), Jason Rhodes (Director), Evan Spiegel (CEO), and Matthew Stanton (Insider). Learn More on Generation Bio's active insiders.

Are insiders buying or selling shares of Generation Bio?

In the last twelve months, Generation Bio insiders bought shares 2 times. They purchased a total of 12,637 shares worth more than $19,159.34. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 11,591 shares worth more than $49,239.96. The most recent insider tranaction occured on January, 2nd when COO Antoinette Paone sold 2,445 shares worth more than $3,960.90. Insiders at Generation Bio own 20.8% of the company. Learn More about insider trades at Generation Bio.

Information on this page was last updated on 1/2/2024.

Geoff McDonough Insider Trading History at Generation Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2021Sell10,000$35.10$351,000.001,184,080View SEC Filing Icon  
See Full Table

Geoff McDonough Buying and Selling Activity at Generation Bio

This chart shows Geoff Mcdonough's buying and selling at Generation Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Generation Bio Company Overview

Generation Bio logo
Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.07
Low: $3.72
High: $4.29

50 Day Range

MA: $2.46
Low: $1.73
High: $4.07

2 Week Range

Now: $4.07
Low: $0.86
High: $6.98

Volume

441,905 shs

Average Volume

280,852 shs

Market Capitalization

$270.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.7